Clinical Data AstraZeneca lung drug gets ‘surprise’ win in COPD trials BioPharma DiveThe treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent.Clinical DataRespiratoryRead full story pharminent March 27, 2026 (Last updated: March 30, 2026) BioPharma Dive The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent. Clinical DataRespiratoryRead full story Post navigation Previous: Novartis targets Xolair successor in buyout of startup ExcellergyNext: Otsuka picks up PTSD drug with $700M Transcend buy Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026